Skip to main content

Acumen Pharmaceuticals, Inc.

ABOS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001576885

No open-market purchases or sales by Acumen Pharmaceuticals, Inc. insiders were filed in the last 90 days; 96 institutions reported holding it in 13F filings for Q2 2026, worth $127.8M in total; no superinvestor holds it.

Q4 2023 vs. Q3 2023

How the institutions holding Acumen Pharmaceuticals, Inc. changed between Q3 2023 and Q4 2023.

All holders in Q4 2023All holders in Q3 2023

13F holders of ABOS: Q3 2023 compared with Q4 2023
MeasureQ3 2023Of which not filed for Q4 2023Q4 2023Change
Holders66167+2
Shares43.2M478.8K38.4M−4.27M (−10.0%)
Value$179.2M$1.99M$147.6M−$29.6M (−16.7%)

1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so the changes leave them out.

New holders (20)

Institutions that held Acumen Pharmaceuticals, Inc. at the end of Q4 2023 but not at the end of Q3 2023.

Institutions new to ABOS in Q4 2023
InstitutionSharesValue% of portfolio
Pathstone Holdings, LLC479,149$1.84M0.01%
Tang Capital Management LLC246,895$948.1K0.09%
Man Group plc144,630$555.4K0.00%
D. E. Shaw & Co., Inc.138,029$530.0K0.00%
Acadian Asset Management LLC91,496$350.0K0.00%
683 Capital Management, LLC78,431$301.2K0.03%
Squarepoint Ops LLC52,829$202.9K0.00%
Cubist Systematic Strategies, LLC33,905$130.2K0.00%
ExodusPoint Capital Management, LP32,256$124.0K0.00%
Prelude Capital Management, LLC29,100$111.7K0.01%
Virtu Financial LLC23,787$91.0K0.01%
Susquehanna Portfolio Strategies, LLC21,903$84.1K0.00%
Balyasny Asset Management LLC20,578$79.0K0.00%
Y-Intercept (Hong Kong) Ltd19,348$74.3K0.01%
Occudo Quantitative Strategies LP16,929$65.0K0.01%
Stifel Financial Corp16,150$62.0K0.00%
Group One Trading, L.P.7,543$29.0K0.00%
Point72 Asia (Singapore) Pte. Ltd.2,000$7.68K0.00%
Global Retirement Partners, LLC2,000$7.26K0.00%
Advisory Services Network, LLC1,000$3.84K0.00%

Sold out (18)

Institutions that held Acumen Pharmaceuticals, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.

Institutions that sold out of ABOS in Q4 2023
InstitutionShares, Q3 2023Value, Q3 2023
Deep Track Capital, LP2,513,044$10.4M
Boxer Capital, LLC2,206,983$9.16M
Great Point Partners LLC1,074,101$4.46M
Altium Capital Management LP650,000$2.70M
Ghost Tree Capital, LLC150,000$622.5K
Bridgeway Capital Management, LLC115,033$477.4K
Wellington Management Group LLP104,359$433.1K
Renaissance Technologies LLC87,400$363.0K
UBS Oconnor LLC69,538$288.6K
DekaBank Deutsche Girozentrale40,000$167.0K
Marshall Wace, LLP25,492$105.8K
Verition Fund Management LLC23,500$97.5K
Pinnacle Associates Ltd18,020$74.8K
Pinnacle Wealth Management Advisory Group, LLC18,020$74.8K
XTX Topco Ltd16,538$68.6K
China Universal Asset Management Co., Ltd.1,481$6.15K
FMR LLC657$2.73K
Daiwa Securities Group Inc.165$1.00K

Not filed for Q4 2023 yet (1)

Institutions that held Acumen Pharmaceuticals, Inc. at the end of Q3 2023 and haven't filed a 13F for Q4 2023. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding ABOS in Q3 2023 that haven't filed for Q4 2023
InstitutionShares, Q3 2023Value, Q3 2023
Pathstone Family Office, LLC478,790$1.99M